Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Enalapril (compound)


PubChem
Name: Enalapril
PubChem Compound ID: 5362032
Description: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension.
Molecular formula: C20H28N2O5
Molecular weight: 376.447 g/mol
Synonyms:
Bonuten; L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)-; 172964-46-4; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester; Enalapril Richet; Gadopril; Kinfil; Enalaprila [INN-Spanish]; L-Proline, N-((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-; 75847-73-3.
show more »
DrugBank
Identification
Name: Enalapril
Name (isomeric): DB00584
Drug Type: small molecule
Description: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension.
Synonyms:
Enalaprila [INN-Spanish]; Enalaprilat; Enalapril Maleate; Enalaprilum [INN-Latin]
Brand: Vasotec IV, Vasotec, Gadopril, Bonuten, Kinfil
Brand name mixture: Vaseretic(enalapril maleate + hydrochlorothiazide), Lexxel(enalapril maleate + felodipine)
Category: Angiotensin-converting Enzyme Inhibitors, Antihypertensive Agents
CAS number: 75847-73-3
Pharmacology
Indication: For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.
Pharmacology:
Enalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat following oral administration. Enalapril itself has little pharmacologic activity. Enalaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympa...
show more »
Mechanism of Action:
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, w...
show more »
Absorption: 55-75%, absorption is unaffected by food; enalaprilat (clinically administered IV) is poorly absorbed, 3-12%, due to its high polarity.
Protein binding: 50-60% of enalaprilat is bound to plasma proteins
Biotransformation: ~ 60% of absorbed dose is extensively hydrolyzed to enalaprilat, primarily by liver esterases
Route of elimination: Excretion of enalapril is primarily renal.
Half Life: < 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.
Toxicity: Overdosage may result in marked hypotension and stupor. Most common adverse effects include hypotension, headache, dizziness and fatigue.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Herbs that may attenuate the antihypertensive effect of enalapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
Enalapril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
High salt intake may attenuate the antihypertensive effect of enalapril.
Take without regard to meals.
Drug interaction:
RifampinRifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.
LithiumThe ACE inhibitor increases serum levels of lithium
TizanidineTizanidine increases the risk of hypotension with the ACE inhibitor
TobramycinIncreased risk of nephrotoxicity
SpironolactoneIncreased risk of hyperkalemia
show more »

Targets


Enzymes


Transporters